AstraZeneca chief claims vindication five years after Pfizer bid
Some investors and analysts still unconvinced UK company was right to resist approach (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 24, 2019 Category: Pharmaceuticals Source Type: news

Lower Dose of Pfizer-Lilly Painkiller Misses Main Goals in Late Stage Study Lower Dose of Pfizer-Lilly Painkiller Misses Main Goals in Late Stage Study
A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday in releasing topline results of the study.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 22, 2019 Category: Orthopaedics Tags: Anesthesiology News Source Type: news

Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis
The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee. (Source: World Pharma News)
Source: World Pharma News - April 22, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Keytruda, Pfizer combo gets FDA ok for advanced kidney cancer
The U.S. FDA approved Merck's blockbuster Keytruda in combination with Pfizer's Inlyta as a first-line treatment for advanced renal call carcinoma — kidney cancer that has spread, despite earlier treatments. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 22, 2019 Category: Pharmaceuticals Source Type: news

Low dose Pfizer-Lilly painkiller fails late stage study
A lower dose of non-opioid painkiller, tanezumab, developed by Pfizer and Eli Lilly failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 19, 2019 Category: Pharmaceuticals Source Type: news

Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study
A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - April 19, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

ViiV two-drug HIV combo wins U.S approval
The organization is GSK ’s HIV drugs division where Pfizer and Shionogi& Co have stakes as well (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 9, 2019 Category: Pharmaceuticals Source Type: news

With Pfizer deal, Concerto HealthAI notches another friend in pharma
The companies'partnership is yet another example of real-world data analysis coming to clinical trials. (Source: mobihealthnews)
Source: mobihealthnews - April 9, 2019 Category: Information Technology Source Type: news

FDA Expands Use of Breast Cancer Drug to Men FDA Expands Use of Breast Cancer Drug to Men
The agency extended the indication of the advanced breast cancer drug palbociclib (Ibrance, Pfizer) to include male patients.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 4, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

6 Ways to Save Money on Prescription Drugs
The cost of prescription drugs in the U.S. has long caused frustration and, worse, presented financial barriers for some consumers. According to the Organisation for Economic Co-operation and Development, the average American pays $1,200 per year for medications, more than in any other country in the world. A recent poll from Kaiser Family Foundation found that 29% of American adults are not taking medications as directed, either skipping or splitting doses, opting for over-the-counter medication instead or not filling their prescriptions at all, in order to cut costs. Currently, the U.S. government doesn’t regulate ...
Source: TIME: Health - April 4, 2019 Category: Consumer Health News Authors: Sonia Weiser Tags: Uncategorized medicine Source Type: news

FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
April 4, 2019 -- Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for Ibrance (palbociclib) in combination with an aromatase inhibitor or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 4, 2019 Category: Drugs & Pharmacology Source Type: news

Another Promising Alzheimer ’ s Drug Trial Ends In Failure: ‘ This One Hurts ’
(CNN) — It’s another devastating blow in the search for a treatment for patients living with Alzheimer’s disease. Pharmaceutical giant Biogen and its Japanese partner Eisai announced Thursday they were halting two phase three clinical trials of a drug that targets the buildup in the brain of beta-amyloid, one of two proteins that researchers believe contribute to the development of Alzheimer’s. The drug, called aducanumab, was the most promising candidate in a field that has been littered with failures. It was so promising that the company was running two phase three trials simultaneously, said neur...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 21, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Alzheimer's Disease CNN Source Type: news

Biogen Halts Promising Alzheimer ’s Drug Trials Due to Disappointing Results
Pharmaceutical company Biogen is halting two global phase-three trials testing the once-promising Alzheimer’s drug aducanumab, delivering a late-stage blow to researchers searching for therapies for the incurable degenerative disease. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience,” Biogen CEO Michel Vounatsos said in a statement Thursday. “We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly...
Source: TIME: Health - March 21, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs onetime Source Type: news

Pfizer buys stake in French gene company in deal worth up to $636M
Pfizer Inc. said it's buying a stake in a French gene company in a deal that could be worth up to $636 million. The New York drug company (NYSE: PFE) said it's paying $51 million upfront to acquire a 15 percent stake in Vivet Therapeutics of Paris. Vivet is working on a drug — VTX-801 — to treat Wilson disease, which is a rare and possibly fatal condition in which excess copper collects in the body's l iver and other organs, perhaps to life-threatening levels. “VTX-801 could provide a potentially… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 21, 2019 Category: Health Management Authors: Ben Miller Source Type: news

Pfizer buys stake in French gene company in deal worth up to $636M
Pfizer Inc. said it's buying a stake in a French gene company in a deal that could be worth up to $636 million. The New York drug company (NYSE: PFE) said it's paying $51 million upfront to acquire a 15 percent stake in Vivet Therapeutics of Paris. Vivet is working on a drug — VTX-801 — to treat Wilson disease, which is a rare and possibly fatal condition in which excess copper collects in the body's l iver and other organs, perhaps to life-threatening levels. “VTX-801 could provide a potentially… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 21, 2019 Category: Biotechnology Authors: Ben Miller Source Type: news

Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
PARIS & Vivet Therapeutics ("Vivet"), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. (Source: World Pharma News)
Source: World Pharma News - March 21, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Pfizer invests in French gene therapy co.
Pfizer announced it has acquired a 15 percent stake in Vivet Therapeutics, with an exclusive option to fully acquire the privately-held French gene therapy company. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 20, 2019 Category: Pharmaceuticals Source Type: news

Should Medicine Offer Money-Back Guarantees? Should Medicine Offer Money-Back Guarantees?
Pfizer will offer partial rebates to Chinese patients for the drug palbociclib if their disease progresses.Medscape Reader Polls (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 20, 2019 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Hospira, Inc. Issues a Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP Due to the Presence of Particulate Matter
Hospira, Inc., a Pfizer company, is voluntarily recalling lot numbers 79-238-EV, 79-240-EV and 80-088-EV, NDC# 0409-6625-02, of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL), to the Hospital/Institution level. The recall was initiated due to the presence of particulate matter, confirmed as glass. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 15, 2019 Category: Food Science Source Type: news

Pfizer ’s Herceptin biosimilar wins FDA nod
Roche ’s blockbuster cancer treatment, Herceptin, will now face increasing competition from a new biosimilar. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Pfizer's biosimilar to Roche's Herceptin
The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - March 11, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin
March 11, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the treatment of human epidermal growth factor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 11, 2019 Category: Drugs & Pharmacology Source Type: news

Teva launches generic for Pfizer ’s Flector pain patch
Teva (NYSE:TEVA) said last week that it launched a generic version of Pfizer‘s (NYSE:PFE) Flector diclofenac epolamine patch. Using a nonsteroidal anti-inflammatory drug, the topical patch is designed to treat acute pain due to minor strains, sprains and contusions. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches generic for Pfizer’s Flector pain patch appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 4, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Pain Management Pharmaceuticals Wall Street Beat Pfizer Teva Pharmaceuticals Source Type: news

U.S. attorney investigating quality issues at St. Louis EpiPen plant, Pfizer says
Pfizer Inc. said Thursday it received a request for documents as part of a U.S. investigation into quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site, in St. Louis. The demand was from the U.S. Attorney's office for the Southern District of New York, Pfizer said, according to Reuters. The news agency reports that Pfizer unit Meridian, which makes the EpiPen injectors used to deliver an emergency allergy antidote, has been hit with manufacturing… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 1, 2019 Category: American Health Authors: Jacob Kirn Source Type: news

Pfizer unit Meridian under civil investigation by U.S. Attorney
Pfizer Inc said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site. (Source: Reuters: Health)
Source: Reuters: Health - March 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA warns of blood clots and death associated with higher dose of Pfizer's Xeljanz
A safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of the drug was used in patients with rheumatoid arthritis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 26, 2019 Category: Pharmaceuticals Source Type: news

Pfizer, Ochsner Health team up for clinical trial innovation
The pharma company and health system are looking to create digital tools to help make clinical trials easier for patients, clinicians and researchers.   (Source: mobihealthnews)
Source: mobihealthnews - February 20, 2019 Category: Information Technology Source Type: news

Merck, Pfizer post positive results for kidney cancer combo
A combination of treatments from Merck and Pfizer has shown to extend the life of patients with advanced kidney cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 19, 2019 Category: Pharmaceuticals Source Type: news

Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
NEW YORK and INDIANAPOLIS, Feb. 19, 2019 -- (Healthcare Sales & Marketing Network) -- Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with modera... Biopharmaceuticals Eli Lilly, Pfizer, tanezumab, low back pain (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 19, 2019 Category: Pharmaceuticals Source Type: news

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial
A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - February 19, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Higher dose of Pfizer-Lilly drug helps reduce back pain in study
Pfizer and Eli Lilly said on Tuesday that a higher dose of their non-opioid drug tanezumab succeeded in reducing chronic low back pain in patients in a late-stage clinical study. (Source: Reuters: Health)
Source: Reuters: Health - February 19, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Ochsner Health System and Pfizer partner to develop innovative models for clinical trials
NEW ORLEANS & Ochsner Health System, Louisiana's largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials. (Source: World Pharma News)
Source: World Pharma News - February 19, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Merck, Pfizer drug combo extends kidney cancer survival: study
A combination of Merck& Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - February 16, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Bayer stresses drug's tolerability in bid for prostate cancer market
Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson& Johnson. (Source: Reuters: Health)
Source: Reuters: Health - February 14, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Merck, Pfizer combo treatment boosts kidney cancer survival
Drugmaker Merck& Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent. (Source: Reuters: Health)
Source: Reuters: Health - February 12, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer Japan recalls high blood pressure drug over cancer-causing impurity
The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer Japan recalls high blood pressure drug Amvalo due to carcinogen
The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a substance that can cause cancer, the drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
In conjunction with World Cancer Day, the Union for International Cancer Control (UICC) and Pfizer Inc. announce the third round of the Seeding Progress And Resources for the Cancer Community (SPARC): Metastatic Breast Cancer (MBC) Challenge: their pioneering grants initiative designed to (Source: World Pharma News)
Source: World Pharma News - February 8, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Wyss Center neurologist awarded prestigious Pfizer Research Prize
(Wyss Center for Bio and Neuroengineering) Maxime Baud, MD, PhD, Staff neurologist at the Wyss Center and epileptologist at the University of Bern and Geneva University Hospitals (HUG), was awarded the Pfizer Research Prize for his work in the field of neuroscience and nervous system disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2019 Category: International Medicine & Public Health Source Type: news

Trastuzumab Biosimilar Proves Mettle in Two Breast Ca Trials (CME/CE)
(MedPage Today) -- Pfizer's biosimilar efficacious and safe for first-line treatment as a branded trastuzumab (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 8, 2019 Category: Hematology Source Type: news

CEOs from some of pharma ’s biggest companies to testify to the Senate
The heads of Pfizer, Merck, Bristol-Myers Squibb and Sanofi have agreed to testify at a Senate hearing on drug prices later this month. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 7, 2019 Category: Pharmaceuticals Source Type: news

At least four pharma CEOs to testify at Senate drug pricing hearing
Drugmakers Pfizer Inc, Bristol-Myers Squibb Co and Sanofi SA said on Wednesday that their chief executives plan to testify at a Senate hearing on rising prescription drug prices later this month. (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer CEO Bourla plans to testify at Senate drug pricing hearing
U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescription drug prices. (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer's Trastuzumab Biosimilar Noninferior in Two Breast Ca Trials
(MedPage Today) -- Results similar to branded drug in metastatic, neoadjuvant breast cancer studies (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 4, 2019 Category: OBGYN Source Type: news

Pfizer receives positive CHMP opinion for Vizimpro ® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations
Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in the European Union (EU) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. (Source: World Pharma News)
Source: World Pharma News - February 1, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Pfizer and Lilly osteoarthritis pain drug grabs another win
The pair of drugmakers announced that its drug tanezumab reduced pain significantly at the higher of two doses tested, with a phase 3 trial from last year also showing efficacy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 29, 2019 Category: Pharmaceuticals Source Type: news

Pfizer sees strong dollar weighing on results in 2019
US pharmaceutical group said greenback will result in a $900m hit to full-year revenue (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 29, 2019 Category: Pharmaceuticals Source Type: news

Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company SOUTH SAN FRANCISCO, Calif., Jan. 29, 2019 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced the appointment of Andreas Maderna, Ph.D., ... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, immunotherapy, immuno-oncology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 29, 2019 Category: Pharmaceuticals Source Type: news

Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain. The tanezumab 5 mg treatment arm met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients' overall assessment of their OA compared to those receiving placebo. (Source: World Pharma News)
Source: World Pharma News - January 29, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Senior hire adds 25 years of highly relevant leadership, technical operations and supply chain experience from Pfizer and Ipsen to Actinium's Executive Team Ms. Pussinen to lead technical and supply chain efforts to drive forward Actinium's multi-diseas... Biopharmaceuticals, Oncology, Personnel Actinium Pharmaceuticals, Iomab-B, bone marrow transplant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2019 Category: Pharmaceuticals Source Type: news